Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chemotherapy for retinoblastoma. Ophthalmol Clin North Am. 2005;18:55–63.

Article  PubMed  Google Scholar 

Salim A, Wiknjosastro GH, Danukusumo D, Barnas B, Zalud I. Fetal retinoblastoma. J Ultrasound Med. 1998;17:717–20.

Article  CAS  PubMed  Google Scholar 

Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist. 2007;12:1237–46.

Article  PubMed  Google Scholar 

English MW, Skinner R, Pearson AD, Price L, Wyllie R, Craft AW. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer. 1999;81:336–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grumme L, Biewald E, Reschke M, Fischhuber K, Hanbucken A, Schluter S, et al. Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. Pediatr Blood Cancer. 2022;69:e29362.

Article  PubMed  Google Scholar 

Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52:637–43.

Article  PubMed  Google Scholar 

Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50:223–6.

Article  PubMed  Google Scholar 

Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30:1034–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smits C, Swen SJ, Theo Goverts S, Moll AC, Imhof SM, Schouten-van Meeteren AY. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer. 2006;42:492–500.

Article  CAS  PubMed  Google Scholar 

Soliman SE, D’Silva CN, Dimaras H, Dzneladze I, Chan H, Gallie BL. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience. Pediatr Blood Cancer. 2018;65:e26931.

Article  PubMed  Google Scholar 

Berry JL, Jubran R, Lee TC, Murphree AL, Lee D, Kim JW. Low-dose chemoreduction for infants diagnosed with retinoblastoma before 6 months of Age. Ocul Oncol Pathol. 2015;1:103–10.

Article  PubMed  PubMed Central  Google Scholar 

de Bree R, Moll AC, Imhof SM, Buter J, Leemans CR. Subsequent tumors in retinoblastoma survivors: the role of the head and neck surgeon. Oral Oncol. 2008;44:982–5.

Article  PubMed  Google Scholar 

Jenkinson H. Retinoblastoma: diagnosis and management—the UK perspective. Arch Dis Child. 2015;100:1070–5.

Article  PubMed  Google Scholar 

Munier FL, Mosimann P, Puccinelli F, Gaillard MC, Stathopoulos C, Houghton S, et al. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment. Br J Ophthalmol. 2017;101:1086–93.

Article  PubMed  Google Scholar 

Kivela TT, Hadjistilianou T. Neonatal retinoblastoma. Asia Pac J Oncol Nurs. 2017;4:197–204.

Article  PubMed  PubMed Central  Google Scholar 

Gobin YP, Dunkel IJ, Marr BP, Francis JH, Brodie SE, Abramson DH. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7:e44322.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanff LM. Precision dosing in children; no small matter. Eur J Cancer. 2022;164:155–6.

Article  CAS  PubMed  Google Scholar 

Nijstad AL, Barnett S, Lalmohamed A, Berenos IM, Parke E, Carruthers V, et al. Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. Eur J Cancer. 2022;164:137–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shields CL, Bas Z, Tadepalli S, Dalvin LA, Rao R, Schwendeman R, et al. Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre. Br J Ophthalmol. 2020;104:1548–55.

PubMed  Google Scholar 

Cole M, Price L, Parry A, Keir MJ, Pearson AD, Boddy AV, et al. Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics. Br J Cancer. 2004;90:60–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lankisch P, Wessalowski R, Maisonneuve P, Haghgu M, Hermsen D, Kramm CM. Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer. 2006;46:767–72.

Article  CAS  PubMed  Google Scholar 

Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51:2022–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Veal GJ, Errington J, Tilby MJ, Pearson AD, Foot AB, McDowell H, et al. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer. 2007;96:725–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng B, Boddy AV, Cole M, Pearson AD, Chatelut E, Rubie H, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer. 1995;31A:1804–10.

Article  CAS  PubMed  Google Scholar 

Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30:2408–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacCarthy A, Birch JM, Draper GJ, Hungerford JL, Kingston JE, Kroll ME, et al. Retinoblastoma: treatment and survival in Great Britain 1963 to 2002. Br J Ophthalmol. 2009;93:38–9.

Article  CAS  PubMed  Google Scholar 

Villanueva G, Sampor C, Moreno F, Alderete D, Moresco A, Pinto N, et al. Subsequent malignant neoplasms in the pediatric age in retinoblastoma survivors in Argentina. Pediatr Blood Cancer. 2022;69:e29710.

Article  PubMed  Google Scholar 

Barnett S, Kong J, Makin G, Veal GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. Br J Clin Pharm. 2021;87:256–62.

Article  CAS  Google Scholar 

Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol. 2002;120:1653–8.

Article  PubMed  Google Scholar 

Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol. 2022;79:102203.

Article  PubMed  PubMed Central  Google Scholar 

Stohr W, Paulides M, Bielack S, Jurgens H, Koscielniak E, Rossi R, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48:140–7.

Article  CAS